References
- Ghosh S. Recognition and management of inflammatory bowel disease. J. R. Coll. Physicians Edinb.35, 50–54 (2005).
- Podolsky DK. Inflammatory bowel diseases. N. Engl. J. Med.347, 417–429 (2002).
- Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol.3, 521–533 (2003).
- Bamias G. Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann. Intern. Med.143, 895–904 (2005).
- Van Assche G, Rugeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol.288, G169–G174 (2005).
- Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv. Immunol.72, 209–253 (1999).
- Leger OJP, Yednock Ta, Tanner L et al. Humanization of a mouse antibody against human α-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies8, 3–14 (1997).
- Gordon FH, Lai CWY, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn’s disease. Gastroenterology121, 268–274 (2001).
- Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348, 15–23 (2003).
- Tubridy N, Behan PO, Capildeo R et al. The effect of antiα-4 integrin antibody on brain lesion activity in MS. Neurology62, 2038–2043 (2004).
- O’Connor PW, Goodman A, Willmer-Hulmer AJ et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology62, 2038–2043 (2004).
- Dalton CM, Miszkiel KA, Barker GJ et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J. Neurol.251, 407–413 (2004).
- Polman CH, O’Connor PW, Havrdova E et al.; for the AFFRIM investigators. A randomized, placebo-controlled trial of natalizumab for randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354, 899–910 (2006).
- Rudick RA, Stuart WH, Calabresi PA et al.; for the SENTINEL investigators. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med.354, 911–923 (2006).
- Ghosh S, Goldin E, Gordon F et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348, 24–32 (2003).
- Sandborn Wj, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353, 1912–1925 (2005).
- Targan SR, Feagan B, Fedorak R et al. Natalizumab for the treatment of active Crohn’s disease: results from the ENCORE trial. Gastroenterology132, 1672–1683 (2007).
- Greenlee JE. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications. Int. Mult. Scler. J.13, 100–107 (2006).
- Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med.353, 369–374 (2005).
- Gordon FH, Rana S, Tahami F et al. Adhesion molecule expression in inflammatory bowel disease patients treated with natalizumab, a humanized antibody to A4 integrin. Gastroenterology118(Suppl. 2), 344 (2000).
- Gordon FH, Pounder RE, Amlot PL et al. The effect of natalizumab, a humanized monoclonal antibody to α-4 integrin on circulating activated leucocytes in active inflammatory bowel disease. Gastroenterology122(Suppl. 1), 434 (2002).
- Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to α-4 integrin. Aliment Pharmacol. Ther.16, 699–705 (2002).
- Van Deventer S, Rutgeerts P, Rask-Madsen J et al. Pharmacokinetics and pharmacodynamics of natalizumab in active Crohn’s disease patients. Gastroenterology12(Suppl. 1), A434 (2002).
- Hyams JS, Wilson DC, Thomas A et al. Natalizumab therapy for moderate to severe Crohn’s disease in adolescents. JPGN44, 185–191 (2007).
- Geboes K, Allison MC, Cortot A et al. Natalizumab decreases inflammatory cells within the colonic lamina propria of patients with active Crohn’s disease: results from ENACT-1. Gastroenterology126, A213 (2004).
- Sands BE, Kozarek R, Spainhour J et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm. Bowel Dis.13, 2–11 (2007).
- Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353, 362–368 (2005).
- Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab – unforeseen consequences. N. Engl. J. Med.353, 414–416 (2005).
- Yousry TA, Habil M, Major EO et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354, 924–933 (2006).
- Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med.353, 375–381 (2005).
Websites
- Natalizumab product monograph www.Tysarbi.com
- Biogen. TOUCH™ Prescribing Program. 2006 www.tysabri.com/touch.html
- Federal Drug and Trade Commission. www.fad.gov/cder/foi/appletter/2006/125104s015LTR.pdf